Skip to main content
SpringerLink
Log in

Reclassification of 400 consecutive glioma cases based on the revised 2016WHO classification

  • Original Article
  • Published:
Brain Tumor Pathology Aims and scope Submit manuscript

Abstract

In this study, we reclassified 400 consecutive glioma cases including pediatric cases, using the revised 2016 WHO classification with samples collected from the Kyushu University Brain Tumor Bank. The IDH1/2, H3F3A, key genetic markers in the 2016 classification, were analyzed using high-resolution melting, with DNA extracted from frozen tissues. The 1p/19q codeletions were evaluated using a microsatellite-based loss of heterozygosity analysis, with 18 markers, to detect loss of the entire chromosome arm. In the integrated diagnosis, 29 oligodendroglioma cases and 28 anaplastic oligodendroglioma cases were diagnosed as “IDH-mutant and 1p/19q-codeleted,” while 2 oligodendroglioma cases and 5 anaplastic oligodendroglioma cases were diagnosed as not otherwise specified (NOS). These “NOS” cases were either IDH-mutants or 1p/19q-codeleted, although characteristic oligodendroglial features were evident histologically. Better overall survival of patients with oligodendroglioma correlated with the molecular characteristic of “IDH-mutant and 1p/19q-codeleted,” rather than the WHO grade. Eleven “glioblastoma, IDH-wild-type” cases were classified as “1p/19q-codeleted”, however, chromosome 10 loss was also detected in 10 out of 11 cases. The 2016 WHO criteria for glioma classification leads to better diagnosis of patients. However, there are technical pitfalls and problems to be solved in the molecular analysis of routine diagnostics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–20

    Article  PubMed  Google Scholar 

  2. Komori T (2017) The 2016 WHO Classification of Tumours of the Central nervous system: the major points of revision. Neurol Med Chir (Tokyo) 57:301–11

    Article  Google Scholar 

  3. Komori T (2017) Updated 2016 WHO classification of tumors of the CNS: turning the corner where molecule meets pathology. Brain Tumor Pathol 34:139–40

    Article  PubMed  Google Scholar 

  4. Louis DN, von Deimling A, Cavenee WK (2016) Diffuse astrocytoma and oligodendroglial tumors—introduction. In: Louis DN, Wiestler OD, Cavenee WK, Ellison DW, Figarella-Branger D, Perry A, Reifenberger G, von Deimling A (eds) WHO classification of tumours of the central nervous system (Revised 4th edition). International Agency for Research on Cancer, Lyon, pp 60–9

    Google Scholar 

  5. Eckel-Passow JE, Lachance DH, Molinaro AM et al (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–508

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Suzuki H, Aoki K, Chiba K et al (2015) Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47:458–68

    Article  CAS  PubMed  Google Scholar 

  7. Hatae R, Hata N, Yoshimoto K et al (2016) Precise DETECTION of IDH1/2 and BRAF hotspot mutations in clinical glioma tissues by a differential calculus analysis of high-resolution melting data. PLoS One 11:e0160489

    Article  PubMed  PubMed Central  Google Scholar 

  8. Hatae R, Hata N, Suzuki SO et al (2017) A comprehensive analysis identifies BRAF hotspot mutations associated with gliomas with peculiar epithelial morphology. Neuropathology 37:191–199

    Article  CAS  PubMed  Google Scholar 

  9. Yoshimoto K, Iwaki T, Inamura T et al (2002) Multiplexed analysis of post-PCR fluorescence-labeled microsatellite alleles and statistical evaluation of their imbalance in brain tumors. Jpn J Cancer Res 93:284–90

    Article  CAS  PubMed  Google Scholar 

  10. Yoshimoto K, Hatae R, Sangatsuda Y et al (2017) Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution. Brain Tumor Pathol 34:103–12

    Article  PubMed  Google Scholar 

  11. Hata N, Yoshimoto K, Hatae R et al (2016) Deferred radiotherapy and upfront procarbazine-ACNU-vincristine administration for 1p19q codeleted oligodendroglial tumors are associated with favorable outcome without compromising patient performance, regardless of WHO grade. Onco Targets Ther 9:7123–7131

    Article  PubMed  PubMed Central  Google Scholar 

  12. Wick W, Hartmann C, Engel C et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874–5880

    Article  CAS  PubMed  Google Scholar 

  13. Cairncross G, Wang M, Shaw E et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–43

    Article  CAS  PubMed  Google Scholar 

  14. van den Bent MJ, Brandes AA, Taphoorn MJ et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344–50

    Article  PubMed  Google Scholar 

  15. van den Bent MJ, Weller M, Wen PY et al (2017) A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics. Neuro Oncol 19:614–24

    Article  PubMed  PubMed Central  Google Scholar 

  16. Mizoguchi M, Kuga D, Guan Y et al (2011) Loss of heterozygosity analysis in malignant gliomas. Brain Tumor Pathol 28:191–196

    Article  PubMed  Google Scholar 

  17. Woehrer A, Hainfellner JA (2015) Molecular diagnostics: techniques and recommendations for 1p/19q assessment. CNS Oncol 4:295–306

    Article  CAS  PubMed  Google Scholar 

  18. Smith JS, Alderete B, Minn Y et al (1999) Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18:4144–4152

    Article  CAS  PubMed  Google Scholar 

  19. Vogazianou AP, Chan R, Backlund LM et al (2010) Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses. Neuro Oncol 12:664–78

    Article  PubMed  PubMed Central  Google Scholar 

  20. Snuderl M, Eichler AF, Ligon KL et al (2009) Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin Cancer Res 15:6430–6437

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Kuga D, Mizoguchi M, Guan Y et al (2008) Prevalence of copy-number neutral LOH in glioblastomas revealed by genomewide analysis of laser-microdissected tissues. Neuro Oncol 10:995–1003

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Reifenberger G, Collins VP, Hartmann C et al (2016) Oligodendroglioma, IDH-mutanta and 1p/19q-codeleted. In: Louis DN, Wiestler OD, Cavenee WK, Ellison DW, Figarella-Branger D, Perry A, Reifenberger G, von Deimling A (eds) WHO Classification of Tumours of the Central Nervous System (Revised 4th edition). International Agency for Research on Cancer, Lyon, pp 60–9

    Google Scholar 

Download references

Acknowledgements

We thank Ms. Fumie Doi for her technical assistance regarding genetic analysis. This study was supported by JSPS KAKENHI Grant Numbers 17K10868, 16K10779 and 17K16652.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, Fukuoka, 812-8582, Japan

    Yojiro Akagi, Koji Yoshimoto, Nobuhiro Hata, Daisuke Kuga, Ryusuke Hatae, Takeo Amemiya, Yuhei Sangatsuda & Koji Iihara

  2. Department of Neuropathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

    Satoshi O. Suzuki & Toru Iwaki

  3. Department of Neurosurgery, Kitakyushu Municipal Medical Center, Kitakyushu, Japan

    Masahiro Mizoguchi

Authors
  1. Yojiro Akagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Koji Yoshimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nobuhiro Hata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daisuke Kuga
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ryusuke Hatae
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takeo Amemiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yuhei Sangatsuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Satoshi O. Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Toru Iwaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Masahiro Mizoguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Koji Iihara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Koji Yoshimoto.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Akagi, Y., Yoshimoto, K., Hata, N. et al. Reclassification of 400 consecutive glioma cases based on the revised 2016WHO classification. Brain Tumor Pathol 35, 81–89 (2018). https://doi.org/10.1007/s10014-018-0313-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10014-018-0313-4

Keywords

Search

Navigation